Intravenous Levetiracetam versus Intravenous Phenytoin for Second line treatment of Pediatrics Convulsive Status Epilepticus - Open label Randomized Controlled Trial

Mamum Kartek0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Presenting with generalized tonic clinic ,generalized clonic,generalized tonic,generalised myoclonic ,focal tonic or focal clonic seizures
•2. Children who had received 2 doses of midazolam
•3. Children who had received 2 doses of midazolam for generalized convulsive seizures lasting more than 5 minutes and continued to have persistent or recurrent convulsions in the emergency department at least 5 minutes after the last dose of benzodiazepines
•4. Patient on maintenance dose of phenytoin and Levetiracetam with bad compliance

•1.Age <3 months and >15 years of age .
•2. Children presenting with absence seizures or infantile spasms .
•3. Convulsive status Epilepticus due to hypocalcemia,hypoglycaemia,hypercalcemia .
•4. Patient had received second line Anticonvulsant during the episode of convulsive status epilepticus .
•5. Patients with arrhythmia .
•6. Patients allergic to Levetiracetam and phenytoin .
•7. Patients already on maintenance dose of phenytoin and Levetiracetam with good compliance .
•8. Seizure controlled with 2 doses of midazolam .
•9. Parents / care providers not giving consent .

发起方

Mamum Kartek